Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition

Nature Medicine

Volumn 22, Issue 7, 2016, Pages 762-770

  Vaccari, Monica ^a   Gordon, Shari N ^a   Fourati, Slim ^b   Schifanella, Luca ^a,c   Liyanage, Namal P M ^a   Cameron, Mark ^b   Keele, Brandon F ^d   Shen, Xiaoying ^e   Tomaras, Georgia D ^e   Billings, Erik ^f   Rao, Mangala ^f   Chung, Amy W ^g   Dowell, Karen G ^h   Bailey Kellogg, Chris ^h   Brown, Eric P ⁱ   Ackerman, Margaret E ⁱ   Vargas Inchaustegui, Diego A ^a   Whitney, Stephen ^j   Doster, Melvin N ^a   Binello, Nicolo ^a   Pegu, Poonam ^a   Montefiori, David C ^k   Foulds, Kathryn ^l   Quinn, David S ^l   Donaldson, Mitzi ^l   Liang, Frank ^m   Loré, Karin ^m   Roederer, Mario ^l   Koup, Richard A ^l   McDermott, Adrian ^l   Ma, Zhong Min ⁿ   Miller, Christopher J ⁿ   Phan, Tran B ^o   Forthal, Donald N ^o   Blackburn, Matthew ^a   Caccuri, Francesca ^a   Bissa, Massimiliano ^a   Ferrari, Guido ^e   Kalyanaraman, Vaniambadi ^j   Ferrari, Maria G ^j   Thompson, DeVon ^j   Robert Guroff, Marjorie ^a   Ratto Kim, Silvia ^f   Kim, Jerome H ^f,t   Michael, Nelson L ^f   Phogat, Sanjay ^p   Barnett, Susan W ^q,s   Tartaglia, Jim ^p   Venzon, David ^a   Stablein, Donald M ^r   Alter, Galit ^g   Sekaly, Rafick Pierre ^b   Franchini, Genoveffa ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MILAN   (Italy)

^d FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^g MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^h Dartmouth Department of Computer Science_Dartmouth College   (United States)

ⁱ DARTMOUTH COLLEGE   (United States)

^j Advanced BioScience Laboratories   (United States)

^k DUKE UNIVERSITY MEDICAL CENTER   (United States)

^l NATIONAL INSTITUTES OF HEALTH   (United States)

^m KAROLINSKA INSTITUTE   (Sweden)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p SANOFI PASTEUR   (France)

^q Novartis Vaccines and Diagnostics Inc   (United States)

^r EMMES CORPORATION   (United States)

^s GLAXOSMITHKLINE   (United States)

^t International Vaccine Institute   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 17; INTERLEUKIN 2; JANUS KINASE; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL KILLER CELL RECEPTOR NKG2A; RECOMBINANT VACCINE; REELIN; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; STAT PROTEIN; ALUMINUM POTASSIUM SULFATE; ALUMINUM SULFATE; ALVAC VACCINE; GP120 PROTEIN, SIMIAN IMMUNODEFICIENCY VIRUS; MEMBRANE PROTEIN; RAS PROTEIN; TRANSCRIPTOME; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ARTICLE; DRUG EFFICACY; HEK293 CELL LINE; HUMAN; HUMAN CELL; IMMUNOGENICITY; INNATE IMMUNITY; LYMPHOID CELL; MICROARRAY ANALYSIS; NATURAL KILLER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RHESUS MONKEY; SIGNAL TRANSDUCTION; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE ACTIVATION; ANIMAL; IMMUNOLOGY; LYMPHOCYTE; MUCOSAL IMMUNITY; RANDOMIZATION; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VACCINE IMMUNOGENICITY;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; IMMUNITY, INNATE; IMMUNITY, MUCOSAL; IMMUNOGENICITY, VACCINE; IMMUNOGLOBULIN G; INTERLEUKIN-17; LYMPHOCYTES; MACACA MULATTA; MEMBRANE GLYCOPROTEINS; RANDOM ALLOCATION; RAS PROTEINS; SAIDS VACCINES; SIGNAL TRANSDUCTION; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTOME; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 84976622734     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4105     Document Type: Article

References (58)

1. Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209-2220 (2009).
2. Haynes, B.F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275-1286 (2012).
3. Rolland, M. et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 490, 417-420 (2012).
4. Tomaras, G.D. et al. Initial B cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J. Virol. 82, 12449-12463 (2008).
5. Fox, C.B. & Haensler, J. An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. Expert Rev. Vaccines 12, 747-758 (2013).
6. Pegu, P. et al. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIVmac251 acquisition in an immunization regimen that mimics the RV-144 Thai trial. J. Virol. 87, 1708-1719 (2013).
7. Franchini, G., Gurunathan, S., Baglyos, L., Plotkin, S. & Tartaglia, J. Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev. Vaccines 3 (suppl. 4), S75-S88 (2004).
8. Vaccari, M. et al. Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure. J. Virol. 87, 3538-3548 (2013).
9. Gottardo, R. et al. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV-144 vaccine efficacy trial. PLoS One 8, e75665 (2013).
10. Nitayaphan, S. et al. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J. Infect. Dis. 190, 702-706 (2004).
11. Nakajima, C. et al. Induction of the chemokine receptor CXCR3 on TCR-stimulated T cells: dependence on the release from persistent TCR triggering and requirement for IFN-γ stimulation. Eur. J. Immunol. 32, 1792-1801 (2002).
12. Chung, A.W. et al. Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function. AIDS 28, 2523-2530 (2014).
13. Ackerman, M.E. et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J. Clin. Invest. 123, 2183-2192 (2013).
14. Kaneko, Y., Nimmerjahn, F. & Ravetch, J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313, 670-673 (2006).
15. Liyanage, N.P. et al. Antiretroviral therapy partly reverses the systemic and mucosal distribution of NK cell subsets that is altered by SIVmac251 infection of macaques. Virology 450-451, 359-368 (2014).
16. Reeves, R.K. et al. Gut inflammation and indoleamine deoxygenase inhibit IL-17 production and promote cytotoxic potential in NKp44+ mucosal NK cells during SIV infection. Blood 118, 3321-3330 (2011).
17. Waddell, S.J. et al. Dissecting interferon-induced transcriptional programs in human peripheral blood cells. PLoS One 5, e9753 (2010).
18. Šedý, J.R. et al. CD160 activation by herpesvirus entry mediator augments inflammatory cytokine production and cytolytic function by NK cells. J. Immunol. 191, 828-836 (2013).
19. Fric, J. et al. NFAT control of innate immunity. Blood 120, 1380-1389 (2012).
20. Bambard, N.D., Mathew, S.O. & Mathew, P.A. LLT1-mediated activation of IFN-γ production in human natural killer cells involves ERK signaling pathway. Scand. J. Immunol. 71, 210-219 (2010).
21. Awad, A. et al. Natural killer cells induce eosinophil activation and apoptosis. PLoS One 9, e94492 (2014).
22. Dedio, J. et al. NOSIP, a novel modulator of endothelial nitric oxide synthase activity. FASEB J. 15, 79-89 (2001).
23. Bogdan, C. Regulation of lymphocytes by nitric oxide. Methods Mol. Biol. 677, 375-393 (2011).
24. Selinger, C. et al. Multiple low-dose challenges in a rhesus macaque AIDS vaccine trial result in an evolving host response that affects protective outcome. Clin. Vaccine Immunol. 21, 1650-1660 (2014).
25. Strbo, N. et al. Cutting edge: novel vaccination modality provides significant protection against mucosal infection by highly pathogenic simian immunodeficiency virus. J. Immunol. 190, 2495-2499 (2013).
26. Underhill, G.H., George, D., Bremer, E.G. & Kansas, G.S. Gene expression profiling reveals a highly specialized genetic program of plasma cells. Blood 101, 4013-4021 (2003).
27. Zhang, Z. et al. Plasmacytoid dendritic cells promote HIV-1-induced group 3 innate lymphoid cell depletion. J. Clin. Invest. 125, 3692-3703 (2015).
28. Ragab, A. et al. Drosophila Ras-MAPK signaling regulates innate immune responses in immune and intestinal stem cells. EMBO J. 30, 1123-1136 (2011).
29. Iborra, S. et al. Hras and Nras are dispensable for T cell development and activation but critical for protective TH1 immunity. Blood 117, 5102-5111 (2011).
30. Liu, X.V., Ho, S.S., Tan, J.J., Kamran, N. & Gasser, S. Ras activation induces expression of Raet1 family NK receptor ligands. J. Immunol. 189, 1826-1834 (2012).
31. Sánchez-Ruiz, J., Mejías, R., García-Belando, M., Barber, D.F. & González-García, A. Ral GTPases regulate cell-mediated cytotoxicity in NK cells. J. Immunol. 187, 2433-2441 (2011).
32. Hudgens, M.G. et al. Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments. J. Infect. Dis. 200, 609-613 (2009).
33. Keele, B.F. et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 105, 7552-7557 (2008).
34. Keele, B.F. et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J. Exp. Med. 206, 1117-1134 (2009).
35. Fenizia, C. et al. TRIM5-α does not affect simian immunodeficiency virus SIVmac251 replication in vaccinated or unvaccinated Indian rhesus macaques following intrarectal challenge exposure. J. Virol. 85, 12399-12409 (2011).
36. Romano, J.W., Williams, K.G., Shurtliff, R.N., Ginocchio, C. & Kaplan, M. NASBA technology: isothermal RNA amplification in qualitative and quantitative diagnostics. Immunol. Invest. 26, 15-28 (1997).
37. Lee, E.M. et al. Molecular methods for evaluation of virological status of nonhuman primates challenged with simian immunodeficiency or simian-human immunodeficiency viruses. J. Virol. Methods 163, 287-294 (2010).
38. Vaccari, M., Trindade, C.J., Venzon, D., Zanetti, M. & Franchini, G. Vaccine-induced CD8+ central memory T cells in protection from simian AIDS. J. Immunol. 175, 3502-3507 (2005).
39. Foulds, K.E., Donaldson, M. & Roederer, M. OMIP-005: quality and phenotype of antigen-responsive rhesus macaque T cells. Cytometry A 81, 360-361 (2012).
40. Dominguez, M.H. et al. Highly multiplexed quantitation of gene expression on single cells. J. Immunol. Methods 391, 133-145 (2013).
41. Tomaras, G.D. et al. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc. Natl. Acad. Sci. USA 110, 9019-9024 (2013).
42. Montefiori, D.C. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr. Protoc. Immunol. Ch, 12 (2005).
43. Schiffner, T. et al. Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking. J. Virol. 87, 10163-10172 (2013).
44. Li, M. et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79, 10108-10125 (2005).
45. Gómez-Román, V.R. et al. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J. Immunol. Methods 308, 53-67 (2006).
46. Hartshorn, K.L. et al. Neutrophil deactivation by influenza A viruses: mechanisms of protection after viral opsonization with collectins and hemagglutination-inhibiting antibodies. Blood 87, 3450-3461 (1996).
47. De Vos, J. et al. Microarray-based understanding of normal and malignant plasma cells. Immunol. Rev. 210, 86-104 (2006).
48. Thongcharoen, P. et al. A phase 1-2 comparative vaccine trial of the safety and immunogenicity of a CRF01-AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J. Acquir. Immune Defic. Syndr. 46, 48-55 (2007).
49. Liang, F. et al. Dendritic cell recruitment in response to skin antigen tests in HIV-1-infected individuals correlates with the level of T cell infiltration. AIDS 27, 1071-1080 (2013).
50. Ackerman, M.E. et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J. Immunol. Methods 366, 8-19 (2011).
51. Benjamini, Y., Drai, D., Elmer, G., Kafkafi, N. & Golani, I. Controlling the false-discovery rate in behavior genetics research. Behav. Brain Res. 125, 279-284 (2001).
52. Brown, E.P. et al. High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. J. Immunol. Methods 386, 117-123 (2012).
53. Boesch, A.W. et al. Highly parallel characterization of IgG Fc binding interactions. MAbs 6, 915-927 (2014).
54. Liquet, B., Lê Cao, K.A., Hocini, H. & Thiébaut, R. A novel approach for biomarker selection and the integration of repeated measures experiments from two assays. BMC Bioinformatics 13, 325 (2012).
55. Gentleman, R.C. et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5, R80 (2004).
56. Troyanskaya, O. et al. Missing value estimation methods for DNA microarrays. Bioinformatics 17, 520-525 (2001).
57. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005).
58. Merico, D., Isserlin, R., Stueker, O., Emili, A. & Bader, G.D. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One 5, e13984 (2010).